Xtant Medical Holdings, Inc. (XTNT)
| Market Cap | 77.43M |
| Revenue (ttm) | 133.93M |
| Net Income (ttm) | 4.97M |
| Shares Out | 140.07M |
| EPS (ttm) | 0.03 |
| PE Ratio | 18.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,490 |
| Open | 0.527 |
| Previous Close | 0.529 |
| Day's Range | 0.523 - 0.568 |
| 52-Week Range | 0.390 - 0.950 |
| Beta | -0.16 |
| Analysts | Strong Buy |
| Price Target | 1.00 (+80.9%) |
| Earnings Date | May 8, 2026 |
About XTNT
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for XTNT stock is "Strong Buy" and the 12-month stock price target is $1.0.
News
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont...
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced suppor...
Xtant Medical Holdings Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $133.9M, with strong gross margin and a return to profitability. 2026 guidance reflects divestitures and non-recurring revenue loss, but core biologics is expected to accelerate as new products and expanded sales force drive growth.
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 3...
Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic condition...
Xtant Medical Holdings Transcript: 2026 CG Musculoskeletal Conference
Strong growth and profitability were driven by vertical integration, product innovation, and strategic divestitures. Expanded product lines and new market entries, including OEM and wound care, support future growth, while a strengthened balance sheet and operational focus position the company for continued success.
Xtant Medical Finalizes Companion Spine Transactions
Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xta...
Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
BELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mo...
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
BELGRADE, Mont. , Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic con...
Xtant Medical Holdings Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth to $33.3M, improved gross margin, and a return to profitability, driven by licensing and biologics. Pending sale of non-core assets will enhance liquidity and focus, with 2025 revenue guidance reiterated at $131–$135M.
Xtant Medical Reports Third Quarter 2025 Financial Results
Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Gr...
Xtant Medical Announces Commercial Launch of CollagenX™
Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont. , Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global...
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
BELGRADE, Mont. , Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The presentation highlighted strong growth, improved profitability, and a sharpened focus on core orthobiologics through divestitures and vertical integration. New product launches and a robust pipeline support expansion into adjacent markets, with no need for additional capital.
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
BELGRADE, Mont. , Sept. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, ortho...
Xtant Medical Holdings Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A high-growth, vertically integrated medtech firm is focusing on regenerative biologics, divesting non-core assets, and expanding its product pipeline with innovations like Trivium and collagen-based products. Strong financials, broad commercial reach, and diversification support future growth.
Xtant Medical Holdings Earnings Call Transcript: Q2 2025
Q2 2025 saw 18% revenue growth, improved gross margin, and a return to profitability, driven by strong biologics performance and licensing revenue. Full-year guidance was raised, and the sale of non-core assets will further strengthen focus and liquidity.
Xtant Medical Reports Second Quarter 2025 Financial Results
Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth...
Xtant Medical to Attend the CG 45th Annual Growth Conference
BELGRADE, Mont. , Aug. 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthop...
Xtant Medical to Announce Second Quarter 2025 Financial Results on August 12, 2025
BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthope...
Xtant Medical Announces Definitive Agreements for the Sale of its Coflex® and CoFix® Spinal Implants and All OUS Businesses to Companion Spine
Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, ...
Xtant Medical Announces the Launch of OsteoFactor Pro™
Allogeneic Growth Factor Solution to Accelerate Bone Repair BELGRADE, Mont. , May 28, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focus...
Xtant Medical Holdings Earnings Call Transcript: Q1 2025
Q1 2025 saw 18% revenue growth to $32.9M, driven by biologics, with a return to profitability and improved margins from vertical integration. FY 2025 guidance was raised to $127–$131M, with strong biologics growth expected and no new capital needed.
Xtant Medical Reports First Quarter 2025 Financial Results
Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont. , May 12, 2025...